<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001354457</cik>
        <entityName>Nasdaq Stock Market LLC</entityName>
    </exchange>

    <issuer>
        <cik>0000891293</cik>
        <entityName>CTI BIOPHARMA CORP</entityName>
        <fileNumber>001-28386</fileNumber>
        <address>
            <street1>501 Elliott Avenue West</street1>
            <street2>Suite 400</street2>
            <city>Seattle</city>
            <stateOrCountryCode>WA</stateOrCountryCode>
            <stateOrCountry>WASHINGTON</stateOrCountry>
            <zipCode>98119</zipCode>
        </address>
        <telephoneNumber>206 282-7100</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>Common Stock</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(a)(3)</ruleProvision>

    <signatureData>
        <signatureName>Tara Petta</signatureName>
        <signatureTitle>AVP</signatureTitle>
        <signatureDate>2023-06-26</signatureDate>
    </signatureData>
</notificationOfRemoval>